Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
Key Points
Key Points
Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.
Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.
The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.
Treatment
...eatment...
...patients who have active malignancy and acute me...
...patients who have active malignancy without addi...
...outine pharmacologic thromboprophylaxis should...
...utine pharmacologic thromboprophylaxis sho...
...tients with cancer (Khorana score [Table 2] ≥2 p...
...ents with multiple myeloma receiving thalidomi...
...l patients with malignant disease...
...rophylaxis with UFH or LMWH should be commen...
Mechanical methods may be added to ph...
...combined regimen of pharmacologic and mechani...
...romboprophylaxis for patients undergoing...
...acologic thromboprophylaxis for up to...
(Updated) Patients who are candidates for exte...
...natively, patients may be offered prophylacti...
...ial anticoagulation may involve LMWH, UFH, fondap...
...long-term anticoagulation, LMWH, edoxaban, rivar...
...nticoagulation with LMWH, direct factor Xa...
...t opinion in the absence of randomize...
...he insertion of a vena cava filter may...
...ts with primary or metastatic central nervous sy...
...l PE and deep vein thrombosis should be treated...
...eatment of isolated subsegmental PE or splan...
...oagulant use is not recommended to improve sur...
...tial variation in risk of VTE between i...
...ts and members of the oncology team shou...
...arding off-label use in guideline recommendati...
...ictive Model for Chemotherapy-assoc...